Document Detail

Mechanism of interferon beta-induced squamous differentiation and programmed cell death in human non-small-cell lung cancer cell lines.
MedLine Citation:
PMID:  7707408     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Non-small-cell lung cancer (NSCLC) is one of the leading causes of cancer-related mortality due largely to the failure of systemic chemotherapy. Thus, new therapeutic paradigms involving the manipulation of normal physiologic growth-regulatory mechanisms, such as terminal cellular differentiation or programmed cell death, are being explored. Interferons may function as antineoplastic agents, in part because of their effects on cell proliferation and differentiation. We have previously demonstrated the antiproliferative and differentiating effects of interferon beta (IFN beta). PURPOSE: The present investigation was designed to study the mechanism of IFN beta on squamous differentiation and/or programmed cell death in cultured NSCLC cells. METHODS: Cross-linked envelope competence and transglutaminase expression and activity were measured in three NSCLC cell lines (NCI-H226, NCI-H358, and NCI-H596) as common markers for squamous differentiation and programmed cell death. DNA fragmentation, as determined by gel electrophoretic analysis, served as a marker for programmed cell death. In addition, the expression of several regulatory and differentiation-related genes (measured by Northern blot analysis of messenger RNA levels) as well as protein kinase C activity was measured to begin to explore possible mechanisms of IFN beta activity. RESULTS: IFN beta-induced cross-linked envelope competence occurred in cell lines with squamous features (NCI-H226 and NCI-H596); conversely, DNA fragmentation occurred in cell lines with glandular features (NCI-H358 and NCI-H596). Stimulation of cross-linked envelope competence by IFN beta was associated with the induction of tissue transglutaminase activity. Both of these parameters were protein-synthesis independent. As previously observed for NCI-H596, IFN beta suppressed the growth of the other two cell lines. Total protein kinase C activity was not altered. Expression of a variety of possibly relevant oncogenes and other genes was variably altered by IFN beta. CONCLUSIONS: IFN beta induces programmed cell death in NSCLC cell lines in a phenotype-specific manner. The programmed cell death pathway represented by cross-linked envelope competence is dependent on the expression of the squamous phenotype and is protein-synthesis independent, suggesting post-translational mechanisms. In addition, squamous differentiation itself may be induced. Changes in gene expression, while not necessary for induction of cross-linked envelope competence, may be involved in other aspects of cellular homeostasis, such as growth suppression. IMPLICATIONS: By inducing terminal cellular differentiation or programmed cell death, IFN beta may be therapeutically useful in NSCLC. The post-translational nature of IFN beta-induced effects suggests that it will be best used in combination with other agents that can regulate these cellular pathways at the pretranslational level, increasing the proportion of cells capable of being driven to a terminal state by this biotherapeutic agent.
A Lokshin; J E Mayotte; M L Levitt
Related Documents :
25449888 - Human umbilical cord mesenchymal stem cells protect against ischemic brain injury in mo...
25319688 - Heterogeneously expressed fezf2 patterns gradient notch activity in balancing the quies...
2144608 - Functional analysis of the murine t-cell receptor beta enhancer and characteristics of ...
25210168 - Early preservation of cxcr5+ pd-1+ helper t cells and b cell activation predict the bre...
21168488 - Reversible targeting and controlled release delivery of daunorubicin to cancer cells by...
18019358 - Good manufacturing practice-compliant expansion of marrow-derived stem and progenitor c...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of the National Cancer Institute     Volume:  87     ISSN:  0027-8874     ISO Abbreviation:  J. Natl. Cancer Inst.     Publication Date:  1995 Feb 
Date Detail:
Created Date:  1995-05-09     Completed Date:  1995-05-09     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  7503089     Medline TA:  J Natl Cancer Inst     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  206-12     Citation Subset:  IM    
Department of Human Oncology, Medical College of Pennsylvania, Pittsburgh, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Apoptosis / drug effects
Blotting, Northern
Carcinoma, Non-Small-Cell Lung / enzymology,  pathology*
Carcinoma, Squamous Cell / enzymology,  pathology*
Cell Differentiation / drug effects
DNA Damage
DNA, Neoplasm
Electrophoresis, Agar Gel
Enzyme-Linked Immunosorbent Assay
Gene Expression Regulation, Enzymologic
Gene Expression Regulation, Neoplastic
Interferon-beta / pharmacology*
Lung Neoplasms / enzymology,  pathology*
Transglutaminases / metabolism
Tumor Cells, Cultured
Reg. No./Substance:
0/DNA, Neoplasm; 77238-31-4/Interferon-beta; EC

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: pr...
Next Document:  Alcohol, low-methionine--low-folate diets, and risk of colon cancer in men.